Overview

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Status:
Recruiting

Trial end date:
2024-01-01

Target enrollment:

Participant gender:

Summary

This is an open label multicenter, Phase IB/II Study of Abemaciclib in Combination with Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Icahn School of Medicine at Mount Sinai

Treatments:

Bicalutamide